RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai HaiHe Biopharma announced a $146.6 million funding to support its portfolio of innovative cancer drugs. HaiHe has partnered with Shanghai Institute of Materia Medica, Chinese Academy of Science to develop novel cancer drugs for global markets. The company is testing ten candidates in clinical trials and five more in preclinical studies. Last year, HaiHe merged with RMX (Shanghai) Pharmaceutical Technology. The financing was led by Huagai Capital, a private equity investor.
Source: China Biotoday
